Back to News
Market Impact: 0.35
Foghorn Drops FHD-909 Development After Phase 1, Shifts Focus To Proprietary Pipeline
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Foghorn Therapeutics said it will not advance its FHD-909 program after reviewing data from the Phase 1 dose-escalation trial. The article provides no trial results or financial impact details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.40
Ticker Sentiment
FHTX-0.75
More News
- Samsung, SK Hynix shares drop as Q3 earnings loom
- CH Robinson to Buy RXO for $5.8B in Bet on AI Model
- BPCE acquires 7% stake in Spain’s Banco Sabadell
- Wells Fargo gets a bold upgrade ahead of earnings. Why the stock can play catch-up
- SpaceX stock climbs to highest since June, returning Musk to trillionaire status
- Nike’s China troubles: What are the implications for other sportswear brands?
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Search Earnings Call Transcripts With AI
- What a Concept From Nature Tells Us About How C-Suite Executives Actually Think About AI